In 2019 a biopsy of my prostate revealed GG4 tumor. The Decipher score was 0.89 and a Foundation One test showed...

Understanding Your Complex Prostate Cancer Situation

Thank you for sharing such detailed information about your journey. Your case illustrates why advanced prostate cancer requires careful, individualized interpretation—and why the tests you've had are important pieces of a larger puzzle. Let me help you understand what's happening and what questions to ask your team.

What Your Test Results Tell Us (General Framework)

Your Initial Risk Factors (2019)

Your original biopsy showed several markers that oncologists use to assess aggressiveness:

• Gleason Grade 4 (GG4): This indicates moderately-to-poorly differentiated cancer cells—more aggressive than lower grades
• Decipher score of 0.89: This genomic test predicts higher risk of metastasis and treatment resistance (scores range 0-1, with higher = more aggressive)
• PTEN and TP53 mutations: These are tumor suppressor genes. When mutated, they can make cancer cells more aggressive and potentially less responsive to standard therapies

What this meant: Your oncology team appropriately treated you with aggressive multimodal therapy (radiation, brachytherapy, and 18 months of hormone therapy).

---

Your PSA Recurrence Pattern (2023 onward)

The fact that your PSA remained undetectable for ~4 years after initial treatment, then rose rapidly, tells an important story:

General clinical reasoning: When PSA rises after a long disease-free period, it typically indicates:

1. Cancer cells that survived initial treatment have developed resistance to hormone therapy
2. The tumor biology may have evolved (become more aggressive or changed its characteristics)
3. This is called "castration-resistant prostate cancer" (CRPC)—meaning the cancer is growing despite hormone suppression

---

Your Current Treatment Response (Mixed Picture)

Here's where your situation becomes particularly important to understand:

What the PSA shows:

• PSA dropping to 0.03 suggests your current regimen (ADT + abiraterone + docetaxel) is working at the molecular level
• This is a meaningful response

What the PET scans show (the complexity):

• First PET (after 6 months on treatment): Uptake in "most met sites" despite low PSA
• Third PET (a year later): Some sites cleared, others still showing uptake

What this pattern means clinically:

According to the CancerPatientLab webinars on advanced cancer management, when you have discordant findings (PSA responding but imaging showing persistent uptake), oncologists must consider several possibilities:

1. Heterogeneous tumor response: Different metastatic sites may respond differently to the same treatment—some cancer cells die while others persist
2. Imaging sensitivity: PSMA PET is highly sensitive and may detect very small amounts of disease that don't yet affect PSA
3. Tumor evolution: Your cancer may be developing different subclones (populations of cells) with varying treatment sensitivities
4. Treatment timing: The relationship between PSA response and imaging changes doesn't always align perfectly

---

The Significance of Your Specific Findings

Your PTEN/TP53 Mutations Matter

These mutations are particularly relevant because:

• PTEN loss is associated with more aggressive prostate cancer and can affect response to hormone therapy
• TP53 mutations indicate loss of a critical "brake" on cancer cell growth and are linked to treatment resistance
• Together, they suggest your tumor has biological features that make it more challenging to treat

According to NCCN Guidelines for prostate cancer, patients with these mutations may benefit from:

• Continued aggressive systemic therapy (which you're receiving)
• Consideration of additional biomarker testing to guide next treatment decisions
• Potentially clinical trials targeting these specific mutations

Your PSA/Imaging Discordance

The fact that your PSA is very low (0.03) while PET scans show persistent uptake is not uncommon in advanced prostate cancer and doesn't necessarily mean treatment failure. However, it does require careful interpretation:

Questions this raises for your oncology team:

1. Are the persistent PET-positive sites the same locations as before, or new sites?
2. Has the intensity of uptake decreased over time (suggesting slow response)?
3. Are there any sites that have completely cleared?
4. What is your team's interpretation of "uptake well below liver"—does this suggest lower disease burden?

---

What Advanced Cancer Patients in Your Situation Should Consider

Based on the CancerPatientLab webinars on precision oncology and advanced cancer management, patients with complex, treatment-resistant disease like yours may benefit from:

1. Comprehensive Tumor Profiling (Beyond Your 2019 Testing)

Your original Foundation One test was valuable, but tumor biology evolves. Consider asking about:

• Updated molecular profiling of current disease (if tissue is available from recent biopsies)
• Tumor microenvironment analysis: According to BostonGene's research presented in CancerPatientLab webinars, understanding the immune landscape of your tumors—whether they're "inflamed," "immune-excluded," or "immune desert"—can inform whether immunotherapy might be beneficial
• Spatial analysis: This newer technology examines not just what immune cells are present, but where they're located in relation to cancer cells—which affects treatment response

2. Serial Testing Over Time

The webinars emphasize that for patients on multiple treatments, serial testing before and after treatment changes provides the most clinical utility. Your team might consider:

• Repeat molecular profiling if you change treatments
• Tracking how your tumor's genetic profile evolves with each therapy

3. Clinical Trial Eligibility

Given your:

• PTEN/TP53 mutations
• CRPC status
• Mixed response pattern
• Aggressive initial biology

You may be eligible for clinical trials targeting:

• PTEN-deficient cancers
• TP53-mutant tumors
• Novel combinations of systemic therapies
• Immunotherapy approaches (especially if your tumor microenvironment shows immune infiltration)

---

Specific Questions to Ask Your Oncology Team

Based on your situation, here are targeted questions that will help you understand your case better:

1. On your current response: "My PSA is very low at 0.03, but the PET scan still shows uptake in several sites. How do you interpret this discordance? Does this mean the treatment is working, or should we be concerned?"

2. On tumor evolution: "My original tumor had PTEN and TP53 mutations. Has my cancer's biology changed since 2019? Would updated molecular testing of my current disease help guide treatment decisions?"

3. On next steps: "If my PSA rises again or the PET scan shows progression, what would you recommend? Are there clinical trials I should know about, particularly those targeting PTEN-deficient or TP53-mutant prostate cancer?"

4. On tumor microenvironment: "Some newer tests look at the immune landscape of tumors—whether they're inflamed or 'cold.' Would understanding my tumor's immune profile help determine if immunotherapy might be beneficial?"

5. On imaging interpretation: "Can you explain what 'uptake well below liver' means in terms of disease burden? Is this a sign of good response, or does it require further investigation?"

6. On treatment duration: "How long do you anticipate continuing my current regimen? What markers would indicate we need to change treatment?"

---

Important Context: Why Your Case Is Complex

Your situation exemplifies why advanced cancer requires individualized interpretation rather than simple rules:

• Your initial aggressive biology (GG4, high Decipher score, PTEN/TP53 mutations) predicted this recurrence pattern
• Your current treatment is producing a PSA response, which is meaningful
• But the persistent PET uptake suggests some disease is more resistant
• This doesn't mean treatment is failing—it means your cancer is heterogeneous (different parts respond differently)

According to NCCN Guidelines for castration-resistant prostate cancer, the approach in your situation typically involves:

• Continuing effective systemic therapy as long as it's tolerated
• Monitoring both PSA and imaging carefully
• Being prepared to add or switch therapies based on progression patterns
• Considering clinical trials for treatment-resistant disease

---

The Bottom Line

Your situation reflects the reality of advanced prostate cancer: mixed responses are common, and they require nuanced interpretation rather than simple "good" or "bad" labels.

The fact that your PSA is responding while imaging shows persistent uptake suggests:

• Your current treatment is having an effect
• Some disease